{"id":43722,"date":"2022-08-11T12:50:46","date_gmt":"2022-08-11T12:50:46","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=43722"},"modified":"2022-09-11T17:00:28","modified_gmt":"2022-09-11T17:00:28","slug":"mpx-vaccine-update-access-doses-safer-mpx-sex","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/43722","title":{"rendered":"MPX vaccine update – access, doses, safer MPX sex"},"content":{"rendered":"
\n
Note: This post is mainly notes and links rather than a full article.<\/em><\/strong><\/div>\n

\"\"<\/a><\/b>WHO MPX vaccine meeting – using a lower dose<\/h2>\n

On 2 August 2022, WHO held an online day workshop about MPX vaccines, gaps in knowledge (many) and designing new studies (virtually nothing has started yet, including in the UK).<\/strong><\/p>\n

One proposal was to use a lower vaccine dose, given a different way. Using 20% doses will increase the currently limited supply by five times. As well as giving more people single doses, it could also give two doses to those who need them.<\/p>\n

The US has already changed to using the new lower dose.<\/p>\n

Rather than being given as a subcutaneous injection, it will be given between the layers of the skin (intradermally). This uses a metal tool to scrape the skin first.<\/p>\n

Slides from the WHO meeting and webcasts in English and French are at this link:<\/p>\n

https:\/\/www.who.int\/news-room\/events\/detail\/2022\/08\/02\/default-calendar\/who-monkeypox-research—what-study-designs-can-be-used-to-address-the-remaining-knowledge-gaps-for-monkeypox-vaccines<\/a><\/p>\n

\n

Evidence supporting the alternative dose and use in the US<\/h2>\n

This study shows why the reduced dose could be used.<\/strong><\/p>\n

Frey et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na\u00efve subjects. (2015) Vaccine, 33(39); 5225-5234. DOI: 10.1016\/j.vaccine.2015.06.075.<\/div>\n
\n
https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X15008762<\/a><\/div>\n<\/div>\n

Information about US move to the new dose.<\/h2>\n

\"\"<\/a><\/strong>FDA.\u00a0Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply. (9 August 2022).
\nhttps:\/\/www.fda.gov\/news-events\/press-announcements\/monkeypox-update-fda-authorizes-emergency-use-jynneos-vaccine-increase-vaccine-supply<\/a><\/p>\n

This article in STAT news discusses some of the cautions, which will also have been considered before the US changes.
\nhttps:\/\/www.statnews.com\/2022\/08\/09\/will-low-dose-vaccination-stretch-the-monkeypox-vaccine-supply-or-backfire<\/a><\/p>\n<\/div>\n

Limited vaccine access – in the UK and globally<\/h2>\n

However difficult the news, the UK has already used most of the first supply of MPX vaccines.<\/strong><\/p>\n

Some of these stocks will need to be held for health workers and other people who are at unavoidable higher risk.<\/p>\n

Many people who wanted the vaccine have not been able to get access. Many of these people are at high risk.<\/p>\n

An additional 100,000 doses have been ordered, but these might not become available for at least 4-6 weeks, maybe not until September\/October.<\/p>\n

Some countries with higher case numbers than the UK will have even less access to vaccines.<\/p>\n